Davunetide acetate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 471137

CAS#: Unknown

Description: Davunetide acetate is an eight amino acid peptide (NAPVSIPQ) that has been shown to provide potent neuroprotection, in vitro and in vivo. Davunetide has been shown to increase memory scores in patients suffering from amnestic mild cognitive impairment, a precursor to Alzheimer's disease and to enhance functional daily behaviors in schizophrenia patients.

Chemical Structure

img
Davunetide acetate
CAS# Unknown
Instruction

Theoretical Analysis

MedKoo Cat#: 471137
Name: Davunetide acetate
CAS#: Unknown
Chemical Formula: C38H64N10O14
Exact Mass: 0.00
Molecular Weight: 884.990
Elemental Analysis: C, 51.57; H, 7.29; N, 15.83; O, 25.31

Price and Availability

Size Price Availability Quantity
10mg USD 320 2 Weeks
25mg USD 650 2 Weeks
50mg USD 980 2 Weeks
Bulk inquiry

Related CAS #: 211439-12-2 (free base); Unknown  

Synonym: Davunetide acetate; AL 108; AL 208; AL-108; AL-208; H2N-L-Asn-L-Ala-L-Pro-L-Val-L-Ser-L-Ile-L-Pro-L-Gln-COOH; NAP (peptide); NAPVSIPQ.

IUPAC/Chemical Name: L-asparaginyl-L-alanyl-L-prolyl-L-valyl-L-seryl-L-isoleucyl-L-prolyl-L-glutamine compound with acetic acid

InChi Key: FKFJZZGKZSKPFE-XVHDDEJMSA-N

InChi Code: InChI=1S/C36H60N10O12.C2H4O2/c1-6-18(4)28(35(56)46-14-8-9-23(46)31(52)41-21(36(57)58)11-12-25(38)48)44-30(51)22(16-47)42-33(54)27(17(2)3)43-32(53)24-10-7-13-45(24)34(55)19(5)40-29(50)20(37)15-26(39)49;1-2(3)4/h17-24,27-28,47H,6-16,37H2,1-5H3,(H2,38,48)(H2,39,49)(H,40,50)(H,41,52)(H,42,54)(H,43,53)(H,44,51)(H,57,58);1H3,(H,3,4)/t18-,19-,20-,21-,22-,23-,24-,27-,28-;/m0./s1

SMILES Code: O=C(N[C@H](C(N[C@H](C(N[C@H](C(N1[C@H](C(N[C@@H](CCC(N)=O)C(O)=O)=O)CCC1)=O)[C@H](CC)C)=O)CO)=O)C(C)C)[C@H]2N(C([C@@H](NC([C@H](CC(N)=O)N)=O)C)=O)CCC2.CC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 884.99 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Morimoto BH, Fox AW, Stewart AJ, Gold M. Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev Clin Pharmacol. 2013 Sep;6(5):483-502. doi: 10.1586/17512433.2013.827403. Epub 2013 Aug 24. PMID: 23971871.


2: Magen I, Gozes I. Davunetide: Peptide therapeutic in neurological disorders. Curr Med Chem. 2014;21(23):2591-8. doi: 10.2174/0929867321666140217124945. PMID: 24533805.


3: Gozes I. NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des. 2011;17(10):1040-4. doi: 10.2174/138161211795589373. PMID: 21524250.


4: Gozes I. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. doi: 10.2174/138161211798072553. PMID: 21902667.


5: Zhang J, Wei SY, Yuan L, Kong LL, Zhang SX, Wang ZJ, Wu MN, Qi JS. Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats. Physiol Behav. 2017 May 15;174:67-73. doi: 10.1016/j.physbeh.2017.02.038. Epub 2017 Feb 28. PMID: 28257938.


6: Magen I, Gozes I. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides. 2013 Dec;47(6):489-95. doi: 10.1016/j.npep.2013.10.011. Epub 2013 Oct 24. PMID: 24210139.


7: Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27. PMID: 24873720; PMCID: PMC4129545.


8: Gozes I. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides. 2011 Feb;32(2):428-31. doi: 10.1016/j.peptides.2010.10.030. Epub 2010 Nov 2. PMID: 21050875.


9: Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 2013 Jun;38(7):1245-52. doi: 10.1038/npp.2013.23. Epub 2013 Jan 16. PMID: 23325325; PMCID: PMC3656368.


10: Shiryaev N, Pikman R, Giladi E, Gozes I. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des. 2011;17(25):2603-12. doi: 10.2174/138161211797416093. PMID: 21728979.


11: Çakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019 Oct;49(14):2307-2319. doi: 10.1017/S0033291719001995. Epub 2019 Aug 23. PMID: 31439071; PMCID: PMC6763537.


12: Bakota L, Brandt R. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease. Drugs. 2016 Mar;76(3):301-13. doi: 10.1007/s40265-015-0529-0. PMID: 26729186; PMCID: PMC4757605.


13: Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res. 2012 Apr;136(1-3):25-31. doi: 10.1016/j.schres.2011.11.001. Epub 2011 Dec 12. PMID: 22169248.


14: Scuderi S, D'Amico AG, Castorina A, Federico C, Marrazzo G, Drago F, Bucolo C, D'Agata V. Davunetide (NAP) protects the retina against early diabetic injury by reducing apoptotic death. J Mol Neurosci. 2014 Nov;54(3):395-404. doi: 10.1007/s12031-014-0244-4. Epub 2014 Feb 2. PMID: 24488575.


15: Ivashko-Pachima Y, Maor-Nof M, Gozes I. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies. PLoS One. 2019 Mar 13;14(3):e0213666. doi: 10.1371/journal.pone.0213666. PMID: 30865715; PMCID: PMC6415897.


16: Gozes I, Shazman S. A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome. Eur J Neurosci. 2023 Jul;58(2):2641-2652. doi: 10.1111/ejn.15920. Epub 2023 Feb 9. PMID: 36669790.


17: Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat. 2012;8:85-93. doi: 10.2147/NDT.S12518. Epub 2012 Feb 9. PMID: 22347799; PMCID: PMC3280109.


18: Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides. 2010 Jul;31(7):1368-73. doi: 10.1016/j.peptides.2010.04.011. Epub 2010 Apr 22. PMID: 20417241.


19: Quraishe S, Cowan CM, Mudher A. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol Psychiatry. 2013 Jul;18(7):834-42. doi: 10.1038/mp.2013.32. Epub 2013 Apr 16. PMID: 23587881; PMCID: PMC3690421.


20: Idan-Feldman A, Schirer Y, Polyzoidou E, Touloumi O, Lagoudaki R, Grigoriadis NC, Gozes I. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis. 2011 Dec;44(3):327-39. doi: 10.1016/j.nbd.2011.06.020. Epub 2011 Jul 27. PMID: 21827858.